PEM IDs 100% of breast cancer lesions in study, Naviscan reports

07/25/2013 | (free registration)

Naviscan reported that a study published in the Journal of Nuclear Medicine showed positron emission mammography with breast cancer radiotracer Cu-64-TP3805 was effective in identifying 100% of malignant lesions in 13 patients. Researchers from Thomas Jefferson University utilized PEM imaging with Cu-64-TP3805 and F-18 FDG PET and were able to detect 20 malignant lesions. TP3805 is a compound licensed by NuView Life Sciences that binds to the molecules  expressed on all breast cancer cells early in malignancy.

View Full Article in: (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
Washington DC, DC
Director, Corporate Counsel
Tarrytown, NY